Results
eNauka >
Results >
High doses of imatinib mesylate (800 mg/day) significantly improve rates of major and complete cytogenetic remissions (mcr, ccr) - results from the first planned interim analysis of a multicenter, randomised, 2-arm - phase III study comparing imatinib standard dose (400 mg/day) with imatinib high do
| Title: | High doses of imatinib mesylate (800 mg/day) significantly improve rates of major and complete cytogenetic remissions (mcr, ccr) - results from the first planned interim analysis of a multicenter, randomised, 2-arm - phase III study comparing imatinib standard dose (400 mg/day) with imatinib high do | Authors: | Andreas, A. P.; Bošković, Darinka; Lejniece, S. | Issue Date: | 2008 | Publication: | Haematologica | ISSN: | 0390-6078 Haematologica Search Idenfier |
Publisher: | Pavia : Fondazione Ferrata Storti | Type: | Conference Paper | Collation: | br. Vol. 93 str. 162-162 | VBS COBISS: | 1024764853 | URI: | https://plus.cobiss.net/cobiss/sr/sr/bib/1024764853#izum.si https://enauka.gov.rs/handle/123456789/705479 |
M-category: | Mp. category will be shown later |
Google ScholarTM
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.